Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "aTezolizumab, bevAcizumab, and Cobimetinib (TACo) in Pts With PD1-Refractory Melanoma Brain Metastases"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Elizabeth Burton
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Elizabeth Burton
Login to view comments.
Click here to Login
Skin